Early development evaluation of AZD8081: A substrate for the NK receptors

Drug Development and Industrial Pharmacy

Volumn 37, Issue 6, 2011, Pages 702-713

  Sigfridsson, K ^a,b   Ahlqvist, M ^a   Carlsson, A ^a   Fridstro A ^a  

^a ASTRAZENECA R AND D   (Sweden)

^b CHALMERS UNIVERSITY OF TECHNOLOGY   (Sweden)

Author keywords

drug delivery; Drug development; IBS; NK receptor; preformulation; stability

Indexed keywords

AZD 8081; NEUROKININ 1 RECEPTOR; NEUROKININ 2 RECEPTOR; OPIATE ANTAGONIST; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG FORMULATION; DRUG RELEASE; DRUG SCREENING; DRUG SOLUBILITY; DRUG STABILITY; PH;

ADOLESCENT; ADULT; ANIMALS; AZETIDINES; BENZAMIDES; CRYSTALLIZATION; DELAYED-ACTION PREPARATIONS; DOGS; DRUG DELIVERY SYSTEMS; DRUG STABILITY; DRUG STORAGE; HUMANS; HYDROGEN-ION CONCENTRATION; INTESTINAL SECRETIONS; MALE; RECEPTORS, NEUROKININ-1; RECEPTORS, NEUROKININ-2; SOLUBILITY; WETTABILITY; YOUNG ADULT;

EID: 79955972258     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2010.535823     Document Type: Article

References (34)

1. Pennefather JN, Lecci A, Candenas ML, Patak E, Pinto FM, Maggi CA. (2004). Tachykinins and tachykinin receptors: a growing family. Life Sci, 74:1445-1463. (Pubitemid 38077208)
2. Quartara L, Altamura M. (2006). Tachykinin receptors antagonists: from research to clinic. Curr Drug Targets, 7:975-992. (Pubitemid 44227581)
3. Severini C, Improta G, Falconieri-Erspamer G, Salvadori S, Erspamer V. (2002). The tachykinin peptide family. Pharmacol Rev, 54:285-322. (Pubitemid 34575718)
4. Maggi CA, Patacchini R, Rovero P, Giachetti A. (1993). Tachykinin receptors and tachykinin receptor antagonists. J Auton Pharmacol, 13:23-93. (Pubitemid 23054476)
5. Maggi CA. (1996). Tachykinins in the autonomic nervous system. Pharmacol Res, 33:161-170. (Pubitemid 26300701)
6. Stewart-Lee A, Burnstock G. (1989). Actions of tachykinins on the rabbit mesenteric artery: substance P and [Glp6,L-Pro9]SP6-11 are potent agonists for endothelial neurokinin-1 receptors. Br J Pharmacol, 97:1218-1224. (Pubitemid 20051937)
7. Tsuchida K, Shigemoto R, Yokota Y, Nakanishi S. (1990). Tissue distribution and quantitation of the mRNAs for three rat tachykinin receptors. Eur J Biochem, 193:751-757. (Pubitemid 20381706)
8. Ho WZ, Lai JP, Zhu XH, Uvaydova M, Douglas SD. (1997). Human monocytes and macrophages express substance P and neurokinin-1 receptor. J Immunol, 159:5654-5660. (Pubitemid 127470097)
9. Lai JP, Douglas SD, Ho WZ. (1998). Human lymphocytes express substance P and its receptor. J Neuroimmunol, 86: 80-86. (Pubitemid 28293952)
10. Patacchini R, Maggi CA. (2001). Peripheral tachykinin receptors as targets for new drugs. Eur J Pharmacol, 429:13-21. (Pubitemid 33043978)
11. Naline E, Devillier P, Drapeau G, Toty L, Bakdach H, Regoli D et al. (1989). Characterization of neurokinin effects and receptor selectivity in human isolated bronchi. Am Rev Respir Dis, 140:679-686. (Pubitemid 19234313)
12. Pennefather JN, Zeng XP, Gould D, Hall S, Burcher E. (1993). Mammalian tachykinins stimulate rat uterus by activating NK-2 receptors. Peptides, 14:169-174.
13. Croci T, Aureggi G, Manara L, Emonds-Alt X, Le Fuhr G, Maffrand JP, Mukenge S, Ferla G. (1998). In vitro characterization of tachykinin NK2-receptors modulating motor responses of human colonic muscle stripes. Br J Pharmacol, 124:1321-1327. (Pubitemid 28333959)
14. Saffroy M, Torrens Y, Glowinski J, Beaujouan JC. (2001). Presence of NK2 binding sites in the rat brain. J Neurochem, 79: 985-996. (Pubitemid 33117077)
15. Saffroy M, Torrens Y, Glowinski J, Beaujouan JC. (2003). Autoradiographic distribution of tachykinin NK2 binding sites in the rat brain: comparison with NK1 and NK3 binding sites. Neuroscience, 116:761-773. (Pubitemid 36160572)
16. Massi M, Panocka I, de Caro G. (2000). The psychopharmacology of tachykinin NK-3 receptors in laboratory animals. Peptides, 21:1597-1609.
17. Page NM, Bell NJ. (2002). The human tachykinin NK1 (short form) and tachykinin NK4 receptor: a reappraisal. Eur J Pharmacol, 437:27-30.
18. Patak E, Candenas ML, Pennefather JN, Ziccone S, Lilley A, Martín JD et al. (2003). Tachykinins and tachykinin receptors in human uterus. Br J Pharmacol, 139:523-532. (Pubitemid 36819622)
19. Fioramonti J, Gaultier E, Toulouse M, Sanger GJ, Bueno L. (2003). Intestinal anti-nociceptive behaviour of NK3 receptor antagonism in conscious rats: evidence to support a pheripheral mechanism of action. Neurogastroenterology and Motility, 15:363-369. (Pubitemid 36876251)
20. Lecci A, Maggi CA. (2003). Peripheral tachykinin receptors as potential therapeutic targets in visceral diseases. Expert Opin Ther Targets, 7:343-362. (Pubitemid 36722220)
21. Kramer MS, Cutler N, Feighner J, Shrivastava R, Carman J, Sramek JJ et al. (1998). Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science, 281:1640-1645. (Pubitemid 28435572)
22. Leroy V, Mauser P, Gao Z, Peet NP. (2000). Neurokinin receptor antagonists. Expert Opin Investig Drugs, 9:735-746. (Pubitemid 30175642)
23. Holzer P, Holzer-Petsche U. (2001). Tachykinin receptors in the gut: physiological and pathological implications. Curr Opin Pharmacol, 1:583-590. (Pubitemid 33585999)
24. Lecci A, Valenti C, Maggi CA. (2002). Tachykinin receptor antagonists in irritable bowel syndrome. Curr Opin Investig Drugs, 3:589-601.
25. Wu Y, Loper A, Landis E, Hettrick L, Novak L, Lynn K et al. (2004). The role of biopharmaceutics in the development of a clinical nanoparticle formulation of MK-0869: a Beagle dog model predicts improved bioavailability and diminished food effect on absorption in human. Int J Pharm, 285:135-146. (Pubitemid 39361543)
26. Wan H, Holmén AG, Wang Y, Lindberg W, Englund M, Någård MB et al. (2003). High-throughput screening of pKa values of pharmaceuticals by pressure-assisted capillary electrophoresis and mass spectrometry. Rapid Commun Mass Spectrom, 17:2639-2648. (Pubitemid 37498777)
27. Tannergren C, Petri N, Knutson L, Hedeland M, Bondesson U, Lennernäs H. (2003). Multiple transport mechanism involved in the intestinal absorption and first-pass extraction of fexofenadine. Clinical Pharmacol Ther, 74:423-436. (Pubitemid 37357721)
28. Dressman JB, Amidon GL, Reppas C, Shah VP. (1998). Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms. Pharm Res, 15:11-22. (Pubitemid 28080861)
29. Mortensen PB, Clausen MR, Bonnén H, Hove H, Holtug K. (1992). Colonic fermentation of ispaghula, wheat bran, glucose, and albumin to short-chain fatty acids and ammonia evaluated in vitro in 50 subjects. J Parenter Enteral Nutr, 16:433-439.
30. Nakahara Y, Kida T, Nakatsuji Y, Akashi M. (2005). New fluorescence method for the determination of the critical micelle concentration by photosensitive monoazacryptand derivatives. Langmuir, 21:6688-6695. (Pubitemid 41084454)
31. Amidon GL, Lennernäs H, Shah VP, Crison JR. (1995). A theoretical basis for a biopharmaceutic drg classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res, 12:413-420.
32. Lennernäs H, Abrahamsson B. (2005). The use of biopharmaceutic classification of drugs in drug discovery and development: current status and future extension. J Pharm Pharmacol, 57:273-285. (Pubitemid 40326200)
33. Gupta E, Barends DM, Yamashita E, Lentz KA, Harmsze AM, Shah VP et al. (2006). Review of global regulations concerning biowaivers for immediate release solid oral dosage forms. Eur J Pharm Sci, 29:315-324. (Pubitemid 44602408)
34. Kortejärvi H, Urtti A, Yliperttula M. (2007). Pharmacokinetic simulation of biowaiver criteria: the effects of gastric emptying, dissolution, absorption and elimination rates. Eur J Pharm Sci, 30:155-166. (Pubitemid 46157177)